Algeria Arnaud de Rincquesen – Managing Partner, Deloitte: Companies are willing to come to Algeria. It’s an interesting market. What matters once again is to have a job market. The biggest issue for a company settling in Algeria is to find peo- ple with specialized skills and a good academic level.…

PharmaBoardroom recently conducted a roundtable event with the key opinion leaders of Algeria’s healthcare sector. This is a sample of the conversation at our recent roundtable with senior figures from the Algerian Ministry of Health, AstraZeneca, Novo Nordisk, Clinica, the National Association of Pharmacy Producers, the Chief Economist of the The European Federation of Pharmaceutical…

Algeria PharmaBoardroom recently conducted a roundtable event with the key opinion leaders of Algeria’s healthcare sector. This is a sample of the conversation at our recent roundtable. Algeria’s youthful pharmaceutical landscape includes an array of state-controlled entities of an industrial or commercial nature alongside more conventional regulatory apparatus.  THE NATIONAL AGENCY FOR…

PharmaBoardroom recently conducted a roundtable event with the key opinion leaders of Algeria’s healthcare sector. The sector looks healthy on the surface: it has a market valuation of USD 3 billion, and double-digit sector growth. But now, Algeria must find a way to access more innovative treatments, accommodate existing local players in…

Turkey Multinational R&D investment in Turkey, particularly investment in clinical trials, has been quite limited relative to the size of the Turkish pharmaceutical market. Turkish R&D spending amounted to just 0.95 percent of GDP last year, but the country plans to reach three percent of GDP by 2023. Multinational R&D investment…

Turkey Over the past six years, Turkey has consistently lowered its drugs prices and guided its companies to greater efficiency. “Reference prices in Turkey are constructed from the lowest price in France, Greece, Italy, Spain or Portugal, converted to Turkish Lira at a rate of TRY 1.9595 per EUR,” says Cem…

Turkey In the coming years, Turkey plans to prioritize R&D initiatives, health studies and medical innovation: that’s the core message Minister of Health Mehmet Müezzinoğlu gave PharmaBoardroom. This is the beginning of a new era for healthcare in Turkey. The twenty-first century has already been a period of change in the…

Generics The Moroccan pharma sector is increasingly looking not just to Europe, but also to Africa. Moroccan investment in distribution to African countries is increasing. But key opinion leaders say that challenges remain. For example, Morocco would benefit from a direct export platform. “In the past Morocco always looked towards the north…

healthcare In the past, the Moroccan pharmaceutical sector primarily served local needs. Now it is ramping up its research and development capabilities, looking outwards to global markets, developing partnerships with other African countries, and beginning to think about social programs such as public access to healthcare. “[Morocco’s] success grew from a…

One of the more eye-catching elements of the Algerian government’s public health program has been its radical agenda for the country’s hospitals. Ten brand new University Hospital Centers (CHUs) are to be constructed by 2019, raising the national total to 24, while the existing 14 are set to undergo complete…

doing business Insights from existing players on what to expect and how to succeed in Algeria today. “The key to being successful is to be direct and forthright with the Algerians themselves. Trust in them and they will certainly trust in you.” – Essam Farouk, CEO, El Kendi. “The pace of doing…

investment Newcomers to Algeria’s fledgling, but increasingly vibrant pharmaceuticals sector are immediately struck by the sense of liveliness pervading the industry. Indeed, as growth patterns in developed markets continue to flatten, and the protagonists of ‘big pharma’ pivot towards securing new revenue sources in emergent economies, Algeria must surely constitute one…